Skip to main content
Clinical Trials/NCT01052064
NCT01052064
Unknown
Phase 1

Therapy With rTMS in Children With Attention Deficit and Hyperactivity Disorder. Phase 1 Study.

International Center for Neurological Restoration, Cuba1 site in 1 country20 target enrollmentApril 2009

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Attention Deficit Hyperactivity Disorder
Sponsor
International Center for Neurological Restoration, Cuba
Enrollment
20
Locations
1
Primary Endpoint
Incidence of adverse events
Last Updated
16 years ago

Overview

Brief Summary

Low frequency repetitive Transcranial Magnetic Stimulation(rTMS) is a safe and tolerable procedure in children with Attention Deficit Hyperactivity Disorder(ADHD); it also could be a complement to the treatment of patients with poor symptomatic control to conventional treatment.

Detailed Description

Attention Deficit Hyperactivity Disorder is a common disorder in the infancy; the majority of ADHD have good clinical response to amphetamines alone or in association with antiepileptic drugs. It is described that some patients(10-30%) with ADHD do not respond to conventional pharmacological and psycho- pedagogical treatment; in those patients non invasive brain stimulation methods could be a supplementary option for symptomatic control. There are not many published papers describing the effects of rTMS in persons younger than 18 years; so the first step to extent its use in pediatric population should be to obtain evidences about its tolerance and safety.

Registry
clinicaltrials.gov
Start Date
April 2009
End Date
April 2010
Last Updated
16 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
International Center for Neurological Restoration, Cuba

Eligibility Criteria

Inclusion Criteria

  • Ages eligible for Study: 7years to 12 years
  • Genders Eligible for Study: Both

Exclusion Criteria

  • History of convulsions
  • Co-morbidity with other psychiatric or neurologic disease

Outcomes

Primary Outcomes

Incidence of adverse events

Time Frame: week 1,during treatment

Secondary Outcomes

  • EEG changes in epileptiform or basal activity after treatment compared with the baseline(last day of treatment)

Study Sites (1)

Loading locations...

Similar Trials